Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: A pilot study

Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: A pilot study. We sought to assess the safety and efficacy of enzyme replacement therapy (ERT) with recombinant human-α-galactosidase A (rh-α-Gal A) in kidney transplant recipients with Fabry disease, a previously unstudied population. Three male kidney transplant recipients with biochemically, genetically, and histologically confirmed Fabry disease and documented Fabry myocardiopathy received the rh-α-Gal A, agalsidase beta, 1mg/kg of body weight every 2weeks by intravenous infusion and were monitored biochemically, clinically, and electrocardiographically and echocardiographically for 18months. Patients showed biochemical, clinical/functional, and morphologic response to ERT. Plasma globotriaosylceramide decreased 23% to 50%. Extremity pain resolved within 2months in the patient with this manifestation. On echocardiography, left ventricular mass, end diastolic diameter (EDD), and cardiac contractility, shown by ejection fraction (EF), improved in 2 of the 3 patients receiving essentially all planned infusions. EDD and EF remained basically stable, but cardiac morphologic abnormalities progressed in the other patient, who had a 5-month interruption in ERT after the initial month. Mild mitral insufficiency persisted in all patients, as did atrial fibrillation in the affected individual. After a combined total of 116 infusions, no treatment-related adverse event, intolerance, or seroconversion was seen. Renal function remained stable and the immunosuppression regimen unchanged in all patients. Our pilot study provides preliminary evidence that ERT with agalsidase beta, 1mg/kg every 2weeks, is safe and often effective against extra-renal manifestations in kidney transplant patients with Fabry disease. Studies with longer courses of this and higher doses of ERT are merited in this population.